Related Experiment Video
Updated: Jun 27, 2026
06:48
On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
Published on: May 31, 2020
Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma
Gregory Cairncross1, Robert Jenkins
1Department of Clinical Neurosciences and Hotchkiss Brain, Institute, University of Calgary, Calgary, Alberta, Canada. jgcairnx@ucalgary.ca
Cancer Journal (Sudbury, Mass.)
|December 9, 2008
Summary
Current glioma treatments lack genetic consideration. Oligodendrogliomas with 1p/19q codeletion are sensitive to standard therapies, prompting molecularly-guided clinical trials for targeted treatment approaches.
Area of Science:
- Neuro-oncology
- Molecular Pathology
- Cancer Genetics
Background:
- Glioma treatment relies on light microscopy, overlooking genetic variations like chromosome 1p/19q codeletion.
- Oligodendrogliomas are uniformly treated, lacking targeted therapies for specific genetic alterations.
- Current standards of care include surgical resection and radiotherapy, with radiotherapy's survival benefit extrapolated from glioblastoma studies.
Purpose of the Study:
- To highlight the need for incorporating genetic variability, specifically 1p/19q codeletion, into oligodendroglioma treatment strategies.
- To emphasize the sensitivity of oligodendrogliomas with 1p/19q loss to existing therapies.
- To discuss the emerging trend of molecularly-guided clinical trials for glioma management.
Main Methods:
- Review of current treatment paradigms for gliomas and oligodendrogliomas.
- Analysis of the impact of 1p/19q codeletion on treatment response.
- Discussion of ongoing clinical trials utilizing molecular signatures for patient selection.
Main Results:
- Oligodendrogliomas with 1p/19q loss demonstrate sensitivity to current standard therapies (surgery and radiotherapy).
- These tumors are characterized by slow growth, influencing management decisions.
- The recognition of this molecular subgroup is driving the development of novel, targeted therapeutic approaches.
Conclusions:
- Treatment strategies for oligodendrogliomas should integrate genetic information, particularly 1p/19q codeletion status.
- Molecularly-selected patient cohorts are crucial for advancing targeted therapies in glioma research.
- Future management of oligodendrogliomas will likely be influenced by genetic profiling and tailored treatment plans.
Related Concept Videos
01:04Glial Cells
Overview
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...